Risk-based screening tailors when to start, how often to screen, and which imaging based on your individual risk, rather than age alone.
Evaluation: Family and personal history, hormonal and reproductive factors Breast density Genetic testing for high-risk gene variants A polygenic risk score and a validated risk model
Risk-based breast cancer screening should begin with a formal risk estimate and then select mammography alone versus mammography plus magnetic resonance imaging (MRI); family history, breast density alone, or a single moderate-risk factor does not automatically justify MRI.
The key evidence: the WISDOM trial
It randomized 28,372 women aged 40-74 to a risk-based plan or yearly mammograms, and risk-based screening was noninferior for advanced (stage IIB or later) cancers.
Biopsy numbers were similar between the two groups.
Highest-risk women got mammography and MRI alternating every six months.
Low-risk women aged 40-49 were advised to wait until their risk rose or they turned 50.
Nearly 90% of women chose the risk-based approach, suggesting it’s acceptable to most.
Of those who did the at-home genetic test and carried high-risk variants, 30% had no family history, so family-history-based rules would have missed them.
The authors describe it as showing safety of precision screening, with WISDOM 2.0 now adding improved risk scores for Black women and mammographic AI.
Major guidelines are still mostly age-based, so access to risk-based pathways varies by health system.
The 2024 US Preventive Services Task Force (USPSTF) recommends biennial mammography from age 40 through 74 years for average-risk persons assigned female at birth; this recommendation does not apply to those with a high-risk pathogenic variant, young-age chest radiation, previous breast cancer, or a high-risk breast lesion.
Risk assessment is most useful by approximately age 25–30 and should include:
First- and second-degree relatives on both sides of the family, including ages at diagnosis
Known familial pathogenic variants
Prior chest or mantle-field radiation, particularly before age 30
Prior atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), or lobular carcinoma in situ (LCIS)
Breast density
Reproductive, hormonal, and biopsy history
Match screening intensity to risk
Average risk
Mammography, with digital breast tomosynthesis (DBT) where available, is the primary test.
A US-based option is biennial mammography from 40–74 years; annual versus biennial screening and the stopping age should follow the local guideline and patient preferences.
Routine MRI or ultrasound after a negative mammogram is not established for average-risk dense breasts; the USPSTF considers evidence insufficient. (
Intermediate risk
This includes many women with dense breasts, a personal history of breast cancer, ADH/ALH/LCIS, or an estimated lifetime risk below the high-risk MRI threshold.
Annual mammography or DBT remains the base strategy.
Supplemental MRI can be considered selectively, particularly with extremely dense breasts or additional risk factors.
Ultrasound is an alternative when MRI is unsuitable, but it generally produces more false-positive findings and is less sensitive than MRI. High risk
A calculated lifetime risk of approximately 20% or greater, a pathogenic variant such as BRCA1, BRCA2, PALB2, TP53, or selected other genes, or chest radiation at a young age generally supports annual contrast-enhanced MRI in addition to mammography.
For BRCA1/2 carriers, one National Comprehensive Cancer Network-based framework uses annual MRI at ages 25–29 and annual MRI plus mammography from 30–75 years; after 75, screening is individualized.
MRI and mammography may be performed together annually or alternated every 6 months, depending on the guideline, gene, age, breast density, and local expertise.
A palpable mass, spontaneous unilateral bloody nipple discharge, skin or nipple retraction, or a new focal imaging abnormality requires diagnostic breast imaging, not routine screening intervals.
MRI becomes the usual escalation when lifetime risk is approximately 20% or greater, a relevant pathogenic variant or young-age chest radiation is present, whereas average-risk screening generally remains mammography-based.
